RTW Investments has a series C for the UT Southwestern and Gladstone Institutes spinout, which will progress its lead asset into the clinic.
Tenaya Therapeutics, a US-based developer of therapies for heart disease exploiting Gladstone Institutes and University of Texas Southwestern Medical Center research, collected $106m in a series C round yesterday led by RTW Investments.
GV, a corporate venturing arm of technology conglomerate Alphabet, also took part in the round, as did RA Capital Management, Fidelity, Column Group, Casdin Capital, funds and accounts advised by T Rowe Price Associates and all other existing shareholders.
Founded in 2016, Tenaya’s approach to…
